Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Lan Gao, Dieu Nguyen & Peter Lee. (2022) A systematic review of economic evaluations for the pharmaceutical treatment of chronic lymphocytic leukemia and acute myeloid leukemia. Expert Review of Hematology 15:9, pages 833-847.
Read now
Read now
Ziyan Chen, Yue Cheng, David DeRemer & Vakaramoko Diaby. (2021) Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 923-941.
Read now
Read now
Song Wang, Marie-Hélène Lafeuille, Patrick Lefebvre, Hela Romdhani, Bruno Emond & Mekré Senbetta. (2018) Economic burden of treatment failure in chronic lymphocytic leukemia patients. Current Medical Research and Opinion 34:6, pages 1135-1142.
Read now
Read now
Luis Felipe Casado, Amparo Burgos, Eva González-Haba, Javier Loscertales, Tania Krivasi, Javier Orofino, Carlos Rubio-Terres & Darío Rubio-Rodríguez. (2016) Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. ClinicoEconomics and Outcomes Research 8, pages 475-484.
Read now
Read now
Dirk Müller, Kirsten Fischer, Peter Kaiser, Barbara Eichhorst, Ronald Walshe, Marcel Reiser, Lenka Kellermann, Lisa Borsi, Daniele Civello, Alexander Mensch, Jasmin Bahlo, Michael Hallek, Stephanie Stock & Günter Fingerle-Rowson. (2016) Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leukemia & Lymphoma 57:5, pages 1130-1139.
Read now
Read now
Olena Mandrik, Isaac Corro Ramos, Saskia Knies, Maiwenn Al & Johan L Severens. (2015) Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. Cancer Management and Research 7, pages 279-289.
Read now
Read now
Ursula Rochau, Gaby Sroczynski, Dominik Wolf, Stefan Schmidt, Beate Jahn, Martina Kluibenschaedl, Annette Conrads-Frank, David Stenehjem, Diana Brixner, Jerald Radich, Günther Gastl & Uwe Siebert. (2015) Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leukemia & Lymphoma 56:8, pages 2315-2325.
Read now
Read now
Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2015) Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 20:3, pages 423-447.
Read now
Read now
Articles from other publishers (15)
Vasiliki Iliadou & Kostas Athanasakis. (2023) Sensitivity Analysis in Economic Evaluations of Immuno-Oncology Drugs: A Systematic Literature Review. Value in Health Regional Issues 37, pages 23-32.
Crossref
Crossref
André S. Santos, Jéferson P. de Andrade, Daniela A. Freitas, Érica S.D. Gonçalves, Douglas L. Borges, Lélia M. de A. Carvalho, Kenya V.M. de S. Noronha & Mônica V. Andrade. (2023) Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using a Semi-Markovian Model Approach in R. Value in Health Regional Issues 36, pages 10-17.
Crossref
Crossref
Anuja Chatterjee, Gijs van de Wetering, Ron Goeree, Carolyn Owen, Anne Marie Desbois, Stephane Barakat, Beenish S. Manzoor & Kavita Sail. (2022) A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada. PharmacoEconomics - Open 7:2, pages 199-216.
Crossref
Crossref
László Lorenzovici, László Szilberhorn, Szabolcs Farkas-Ráduly, Andrea Ildiko Gasparik, Andreea Mihaela Precup, Adél Gyöngyvér Nagy, Carsten Utoft Niemann, Tero Aittokallio, Zoltán Kaló & Marcell Csanádi. (2023) Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia. BioDrugs 37:2, pages 219-233.
Crossref
Crossref
Gilles Salles, Martin Barrett, Robin Foà, Joerg Maurer, Susan O’Brien, Nancy Valente, Michael Wenger & David G. Maloney. (2017) Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy 34:10, pages 2232-2273.
Crossref
Crossref
Ursula Becker, Andrew H. Briggs, Santiago G. Moreno, Joshua A. Ray, Phuong Ngo & Kunal Samanta. (2016) Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy. Value in Health 19:4, pages 374-382.
Crossref
Crossref
Simon Frey, Carl R. Blankart & Tom Stargardt. (2016) Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature. PharmacoEconomics 34:5, pages 479-498.
Crossref
Crossref
Karen Lien, Matthew C. Cheung & Kelvin K.W. Chan. (2016) Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review. Journal of Oncology Practice 12:4, pages e369-e379.
Crossref
Crossref
Erkki Soini, Anne Hautala, Eira Poikonen, Ursula Becker, Mira Kyttälä & Janne Martikainen. (2016) Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable. Clinical Therapeutics 38:4, pages 889-904.e14.
Crossref
Crossref
Jagpreet Chhatwal, Michael Mathisen & Hagop Kantarjian. (2015) Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer 121:19, pages 3372-3379.
Crossref
Crossref
Taehwan Park, Scott K. Griggs & Dong-Churl Suh. (2015) Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review. BioDrugs 29:4, pages 259-274.
Crossref
Crossref
Nicoletta Martone, Carlo Lucioni, Silvio Mazzi & Valeria Fadda. (2014) Cost-Effectiveness Evaluation of Oncological Drugs Newly Marketed in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 1:2, pages GRHTA.5000182.
Crossref
Crossref
Saurabh (Rob) Aggarwal. (2014) A survey of breakthrough therapy designations. Nature Biotechnology 32:4, pages 323-330.
Crossref
Crossref
Michael Adena, Jennifer Houltram, Stephen P. Mulligan, Carlene Todd & Grace Malanos. (2014) Modelling the Cost Effectiveness of Rituximab in Chronic Lymphocytic Leukaemia in First-Line Therapy and Following Relapse. PharmacoEconomics 32:2, pages 193-207.
Crossref
Crossref
Jiangning Zhao, Zhenshu Xu, Delong Liu & Quanyi Lu. (2012) Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting. Cancer Cell International 12:1.
Crossref
Crossref